Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.70 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.70 |
| ▸ | HSD17B1 | P14061 | 11/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 11/20 | 0.58 |
| ▸ | ESRRG | P62508 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1181642 | 0.83 | APP (1.00) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL4778599 | 0.80 | APP (0.94) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL15380796 | 0.80 | APP (0.94) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL18876439 | 0.76 | HSD17B1 (0.48) | HSD17B1HSD17B2CYP3A4CYP2C19 | |
| SCHEMBL13335779 | 0.74 | APP (0.81) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL19439597 | 0.74 | DAO (0.42) | — | |
| SCHEMBL12973258 | 0.73 | APP (1.00) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL21143013 | 0.73 | APP (0.34) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL4454574 | 0.73 | APP (0.70) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL14729649 | 0.73 | APP (0.70) | APPESR1ESR2HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| CN-101068803-A | Biaryloxymethylarene carboxylic acid compounds | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, GSK3A | APP 1359/4885ESR1 1085/4885ESR2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.